Metastatic Breast Cancer Clinical Trials

Metastatic Breast Cancer studies recruiting patients for novel treatments. Filter by phase, distance, and inclusion criteria to find your perfect metastatic breast cancer clinical trial.

Condition

Location

Distance

Age

Clinical Trials Metastatic Breast Cancer Clinical Trials

Phase-Based Estimates

Prednisone Or Prednisolonefor Urogenital Neoplasms

The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.

Phase-Based Estimates

Reparixinfor Breast Cancer

Locally Advanced

Primary objective: • To assess the efficacy of reparixin compared to placebo in limiting CRF in adult patients with locally advanced or metastatic breast cancer undergoing single-agent taxane chemotherapy, using FACITFatigue scale. The secondary objectives are: To evaluate change in Quality of Life in the two treatment arms To assess the percentage of patients treated with reparixin compared to placebo delaying and discontinuing chemotherapy To assess Patient Global Impression of Severity (PGI-S) score and Patient Global Impression of Change (PGI-C) score associated with reparixin compared to placebo To assess the effect of reparixin compared to placebo on ECOG PS To assess the effects of reparixin vs placebo on Objective Response Rate (ORR), Progression Free Survival (PFS), Overall Survival (OS) The safety objective is: • To assess the safety and tolerability of reparixin in adult patients undergoing taxane-containing chemotherapy. The pharmacokinetic (PK) objective is: • To define the PK profile of orally administered reparixin, its metabolites (DF2243Y, DF2188Y, ibuprofen) and concomitant antineoplastic agents (paclitaxel, or nab-paclitaxel or docetaxel) in adult patients with locally advanced or metastatic breast cancer.

Phase-Based Estimates

EMB-01for Gastrointestinal Neoplasms

Locally Advanced

This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.

Phase-Based Estimates

Abemaciclibfor Breast Cancer

Los Angeles, CA

Locally Advanced

Los Angeles, CA

This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.

Phase-Based Estimates

Nab-sirolimusfor Neoplasm Metastasis

Locally Advanced

This study is evaluating whether a drug called ABI-009 can help treat a type of cancer called tuberous sclerosis complex.

Phase-Based Estimates

Stereotactic Radiosurgeryfor Cancer, Second Primary

This study is evaluating whether a combination of spinal interstitial laser ablation and stereotactic spine radiosurgery is more effective than either treatment alone.

Phase-Based Estimates

LY3484356for Neoplasm Metastasis

Coon Rapids, MN

Locally Advanced

Coon Rapids, MN

This study is evaluating whether a drug called LY3484356 can help treat breast cancer.

Phase-Based Estimates

BI 1810631for Neoplasm Metastasis

This study is evaluating whether a medicine called BI 1810631 can shrink tumours in people with advanced cancer.

Phase-Based Estimates

V937for Neoplasm Metastasis

Toronto, Canada

Locally Advanced

Toronto, Canada

This study is evaluating whether a combination of two drugs may help treat cancer.

Phase-Based Estimates

PF-07265807for Neoplasm Metastasis

Indianapolis, IN

Locally Advanced

Indianapolis, IN

This study is evaluating whether a drug may help treat cancer.

Phase-Based Estimates

Microwave Ablationfor Lung Cancer

Calgary, Canada

Locally Advanced

Calgary, Canada

This study is evaluating whether a surgery which reduces blood flow in a stomach artery leads to significant weightloss.

Phase-Based Estimates

Survey-based Patient/Clinician Jumpstartfor Neoplasm Metastasis

Locally Advanced

This study is evaluating whether a survey-based patient/clinician Jumpstart guide improves quality of care for patients with chronic illness.

Phase-Based Estimates

EHR-based Clinician Jumpstartfor Kidney Failure

Waitlist Available

Locally Advanced

This study is evaluating whether a clinician-led intervention may help improve the quality of care for patients with chronic illness.

Phase-Based Estimates

IK-175 And Nivolumabfor Carcinoma

Locally Advanced

This study is evaluating whether a drug may help treat advanced or metastatic solid tumors.

Phase-Based Estimates

V938for Neoplasm Metastasis

Toronto, Canada

Waitlist Available

Locally Advanced

Toronto, Canada

This study is evaluating whether a combination of two drugs may help treat cancer.

Phase-Based Estimates

EMB-01for Neoplasm Metastasis

This study is evaluating whether a drug called EMB-01 may help treat solid tumors.

Phase-Based Estimates

Bempegaldesleukinfor Urinary Bladder Cancer

Toronto, Canada

Waitlist Available

Locally Advanced

Toronto, Canada

This study is evaluating whether a drug called NKTR-214 can help treat cancer.

Phase-Based Estimates

Facilitator-Based Interventionfor Cancer

This study is evaluating whether a nurse facilitator can help patients and their families communicate with their doctors and nurses to help them get the care they want.

Phase-Based Estimates

BI 754091for Neoplasm Metastasis

Waitlist Available

Locally Advanced

This is a study in adults with various types of advanced cancer. The purpose of the study is to test a medicine called BI 754091 in combination with several other cancer medicines. BI 754091 is an immunotherapy. This means it may help the immune system fight cancer. Such therapies are also called immune checkpoint inhibitors. How long the participants are in the study depends on whether they benefit from treatment and whether they experience unacceptable side effects. The participants are put into different groups. Each group receives BI 754091 in combination with another medicine. The doctors check whether the tumors shrink or disappear. The doctors also check the general health of the participants.

Phase-Based Estimates

Paclitaxel.for Sarcoma

Locally Advanced

This study is evaluating whether a drug which blocks a certain protein may help treat cancer.

Phase-Based Estimates

MRX-2843for Pathologic Processes

Chapel Hill, NC

Locally Advanced

Chapel Hill, NC

This study is evaluating whether a drug may help treat cancer.

Phase-Based Estimates

Subcutaneous (SC) SEA-CD40for Cancer

Chapel Hill, NC

Waitlist Available

Chapel Hill, NC

This study is evaluating whether SEA-CD40 is safe and effective when given alone, in combination with pembrolizumab, and in combination with pembrolizumab, gemcitabine, and nab-paclitaxel

Phase-Based Estimates

Neratinibfor Breast Cancer

Waitlist Available

This study is to learn if the combination therapy of capmatinib and neritinib can help to control metastatic or locally advanced breast cancer. Researchers also want to find the highest tolerable dose of the combination therapy of capmatinib and neritinib that can be used in this study drug combinations. The safety of this drug combination and the CELsignia MP test methodology will also be studied.

Phase-Based Estimates

Fulvestrantfor Breast Carcinoma

Locally Advanced

NUV-422-03 is a randomized, non-comparative Phase 1/2 dose escalation and expansion study designed to evaluate the safety and efficacy of NUV-422 in combination with fulvestrant relative to NUV-422 monotherapy and fulvestrant monotherapy. The study population is comprised of adults with HR+HER2- aBC. Patients will self-administer NUV-422 orally in 28-day cycles and receive 500 mg fulvestrant intramuscularly (IM) on Days 1 and 15 of Cycle 1 and Day 1 of every cycle thereafter. Patients will be treated until disease progression, toxicity, withdrawal of consent, or termination of the study.

Phase-Based Estimates

Dapagliflozin 10Mg Tabfor Breast Cancer

Kansas City, MO

Kansas City, MO

This study is evaluating whether a drug called dapagliflozin can be used to treat breast cancer.

Phase-Based Estimates

Fulvestrantfor Breast Cancer

Locally Advanced

This study is evaluating whether a drug which is designed to target cancer cells may help treat breast cancer.

Phase-Based Estimates

NUV-422for Glioma

Waitlist Available

Locally Advanced

This study is evaluating whether a drug may help treat brain tumors.

Phase-Based Estimates

Precision Medicinefor Breast Cancer

Salt Lake City, UT

Locally Advanced

Salt Lake City, UT

This study is evaluating whether genomic sequencing and drug screening may help select the best treatment for metastatic breast cancer.

Phase-Based Estimates

Capecitabinefor Triple Negative Breast Neoplasms

Gainesville, FL

Gainesville, FL

This study is evaluating whether a new treatment may help eliminate minimal residual disease in triple negative breast cancer.

Phase-Based Estimates

FES PET/CTfor Breast Cancer

This study is evaluating whether a new imaging technique can help determine the optimal dose of tamoxifen for patients with ESR1 mutations.

Phase-Based Estimates

Sitravatinibfor Breast Cancer

Locally Advanced

This study is evaluating whether a drug called sitravatinib can help treat breast cancer.

Phase-Based Estimates

Abraxanefor Breast Cancer

This study is evaluating whether a drug may help treat cancer.

Phase-Based Estimates

Therapeutic Estradiolfor Breast Cancer

San Francisco, CA

Locally Advanced

San Francisco, CA

This study is evaluating whether a hormone called estrogen may help treat breast cancer.

Phase-Based Estimates

Capecitabinefor Breast Cancer

Waitlist Available

This study is evaluating whether a combination of drugs may help treat breast cancer that has spread to the brain.

Phase-Based Estimates

Niraparibfor Breast Cancer

Philadelphia, PA

Philadelphia, PA

This study is evaluating whether a new drug combination may help treat breast cancer.

Phase-Based Estimates

Simvastatin 80mgfor Breast Cancer

This study is evaluating whether a statin drug may help breast cancer patients respond to anti-HER2 therapy.

Phase-Based Estimates

Atezolizumabfor Adenocarcinoma

Waitlist Available

This study is evaluating whether a combination of drugs may help treat breast cancer.

Phase-Based Estimates

Palbociclibfor Breast Cancer

Waitlist Available

This study is evaluating whether a combination of drugs may help treat breast cancer.

Phase-Based Estimates

Cirmtuzumab + Paclitaxelfor Breast Cancer

Waitlist Available

This study is evaluating whether a drug which targets a protein on the surface of breast cancer cells may help treat breast cancer.

Phase-Based Estimates

Miracle Mouthwash Plus Hydrocortisonefor Cancer

Waitlist Available

This study is evaluating whether a steroid-based mouth rinse can prevent or treat mouth sores in patients taking an aromatase inhibitor plus everolimus.

Phase-Based Estimates

Alisertibfor Breast Cancer

Including Dallas And Austin, TX

Waitlist Available

Including Dallas And Austin, TX

This study is evaluating whether a drug called alisertib in combination with paclitaxel can shrink or slow tumor growth in women with hormone receptor (HR)-positive, HER2-negative or HR-negative, HER2-negative (tri

Phase-Based Estimates

PI3K Inhibitor BYL719for Carcinoma Breast Stage IV

Waitlist Available

This study is evaluating the side effects and best dose of the PI3K inhibitor BYL719 when given together with letrozole in treating patients with hormone receptor-positive metastatic breast cancer.

Phase-Based Estimates

ABT-888for Breast Cancer

Waitlist Available

Locally Advanced

This study is evaluating whether the combination of ABT-888 and temozolomide is safe and effective in treating patients with metastatic breast cancer.

Phase-Based Estimates

Lapatinib, Docetaxel, Trastuzumabfor Breast Cancer

Waitlist Available

This study was designed to find the optimal (best) doses of GW572016, docetaxel, and trastuzumab when given together.

Phase-Based Estimates

Fulvestrant Run-Infor ER-Positive Breast Cancer

The study will investigate if a one month drug holiday from the CDK4/6 inhibitor drug, abemaciclib, will restore the body's sensitivity to the drug and make the subsequent treatment of abemaciclib plus fulvestrant more effective.

Phase-Based Estimates

Pembrolizumabfor Cancer

Kansas City, MO

Kansas City, MO

The primary objective of this Phase 2 Simon 2-Stage study is to determinate the Overall Response Rate (ORR) per RECIST v1.1 following treatment with Imprime PGG + pembrolizumab in patients with ER/PR+/ HER2(-) metastatic breast cancer who have progressed through prior hormone therapy with at least one CDK4/6 inhibitor, and a maximum of 2 subsequent chemotherapy treatment. Patients will be screened for baseline anti-β glucan antibody level (ABA; measured in peripheral blood). Those patients with an ABA greater than or equal to 20 mcg/ml and meeting all other I/E criteria, will be enrolled. The study will enroll 47 patients with 23 patients enrolled into Stage 1. If 4 or more patients in Stage 1 have an objective response after 12 weeks of treatment, the study will proceed into Stage 2. A total of 24 patients will be enrolled in Stage 2 for a total combined population of 47. Overall, objective responses must be observed in 10 patients for the study to be declared a success.

Phase-Based Estimates

Immunocytokine NHS-IL12for Prognostic Stage IV Breast Cancer AJCC v8

This study is evaluating whether NHS-IL12, bintrafusp alfa, and radiation therapy may be a safe and effective treatment for patients with hormone receptor positive, HER2 negative breast cancer that has spread to other places in the body (metastatic).

Phase-Based Estimates

Giredestrantfor Breast Cancer

Waitlist Available

Locally Advanced

This study is evaluating whether a drug called giredestrant may help treat breast cancer.

Phase-Based Estimates

18F-DCFPyLfor Breast Cancer

This study is evaluating whether a protein found in prostate cancer may also be found in breast cancer and may be a factor in resistance to anti-androgen therapies.

Phase-Based Estimates

LY3484356for Endometrial Neoplasms

The Woodlands, TX

Locally Advanced

The Woodlands, TX

This study is evaluating whether a drug may help treat breast and endometrial cancer.

Phase-Based Estimates

Futibatinib Plus Fulvestrantfor Breast Cancer

Calgary, Canada

Locally Advanced

Calgary, Canada

This study is evaluating whether a drug may help treat breast cancer.

Phase-Based Estimates

Ipatasertibfor Breast Cancer

Locally Advanced

This study is evaluating whether a combination of drugs may be effective for treating breast cancer.

Phase-Based Estimates

Palbociclibfor Breast Cancer

Overland Park, KS

Waitlist Available

Locally Advanced

Overland Park, KS

This study is evaluating the recommended dose of palbociclib in combination with letrozole and another medication, Ado-trastuzumab emtansine (T-DM1). Additionally, researchers will determine how well this

Phase-Based Estimates

CFI-400945for Breast Cancer

Toronto, Canada

Locally Advanced

Toronto, Canada

This study is evaluating whether chemotherapy can be used to treat cancer.

Phase-Based Estimates

Ribociclibfor Breast Cancer

Waitlist Available

This study is evaluating whether ribociclib and aromatase inhibitors are safe and effective in treating participants with hormone receptor positive breast cancer that has spread to other places in the body.

Phase-Based Estimates

Ibrutinib 420 Mgfor Breast Cancer

This study is evaluating whether a combination of two drugs may help treat breast cancer.

Phase-Based Estimates

Neratinibfor Breast Cancer

Waitlist Available

Locally Advanced

This study is evaluating whether a drug called Neratinib with and without Fulvestrant as possible treatments for HER2-positive breast cancer.

Phase-Based Estimates

Enzalutamidefor Triple Negative Breast Carcinoma

This study is evaluating whether a combination of two drugs may be more effective than either drug alone in treating breast cancer.

Phase-Based Estimates

Abemaciclibfor Breast Cancer

Waitlist Available

This study is evaluating whether a drug may help treat breast cancer.

Phase-Based Estimates

Abemaciclibfor Breast Cancer

Waitlist Available

This study is evaluating whether a drug called abemaciclib can be used to treat breast cancer.

Phase-Based Estimates

Pembrolizumabfor Carcinoma Breast Stage IV

Waitlist Available

This study is evaluating whether pembrolizumab and doxorubicin hydrochloride works better than pembrolizumab with anti-estrogen therapy in treating patients with triple-negative or hormone-receptor positive breast

Phase-Based Estimates

Margetuximabfor Neoplasm Metastasis

Waitlist Available

This study is evaluating whether a new drug called margetuximab can be used to treat breast cancer.

Phase-Based Estimates

Everolimusfor Breast Cancer

Los Angeles, CA

Waitlist Available

Los Angeles, CA

This study is evaluating whether radium 223 dichloride can be used to treat breast cancer.

Phase-Based Estimates

Palbociclibfor Breast Cancer

Los Angeles, CA

Waitlist Available

Locally Advanced

Los Angeles, CA

This study is evaluating whether a drug called palbociclib can improve the survival of women with breast cancer.

Phase-Based Estimates

AZD2014for Breast Cancer

Waitlist Available

Locally Advanced

This study is evaluating whether a drug called AZD2014 is safe and tolerable when given in combination with a drug called Fulvestrant.

Phase-Based Estimates

Fulvestrantfor Breast Cancer

Waitlist Available

Locally Advanced

Phase IB/II clinical trial of Alpelisb and Tucatinib in patients with PIK3CA-Mutant HER2-positive metastatic breast cancer.

Phase-Based Estimates

DiviTum® TKa Assayfor Breast Cancer

Saint Louis, MO

Locally Advanced

Saint Louis, MO

This study is evaluating whether a blood test can predict which patients with metastatic breast cancer will have a better response to treatment.

Phase-Based Estimates

ARX788for Breast Cancer

This study is evaluating whether a drug may help treat breast cancer.

Phase-Based Estimates

U3-1402for Breast Cancer

Locally Advanced